Cite

Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with <scp>AZD4017</scp> in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase <scp>II</scp> study

MLA

Yogesh Yadav, et al. “Inhibition of 11β‐Hydroxysteroid Dehydrogenase‐1 with AZD4017 in Patients with Nonalcoholic Steatohepatitis or Nonalcoholic Fatty Liver Disease: A Randomized, Double‐blind, Placebo‐controlled, Phase II Study.” Diabetes, Obesity and Metabolism, vol. 24, Jan. 2022, pp. 881–90. EBSCOhost, https://doi.org/10.1111/dom.14646.



APA

Yogesh Yadav, Kelly Dunagan, Rachita Khot, Sudhakar K. Venkatesh, John Port, Alfonso Galderisi, Claudio Cobelli, Craig Wegner, Ananda Basu, Rickey Carter, & Rita Basu. (2022). Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study. Diabetes, Obesity and Metabolism, 24, 881–890. https://doi.org/10.1111/dom.14646



Chicago

Yogesh Yadav, Kelly Dunagan, Rachita Khot, Sudhakar K. Venkatesh, John Port, Alfonso Galderisi, Claudio Cobelli, et al. 2022. “Inhibition of 11β‐Hydroxysteroid Dehydrogenase‐1 with AZD4017 in Patients with Nonalcoholic Steatohepatitis or Nonalcoholic Fatty Liver Disease: A Randomized, Double‐blind, Placebo‐controlled, Phase II Study.” Diabetes, Obesity and Metabolism 24 (January): 881–90. doi:10.1111/dom.14646.